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Abstract 
The greatest potential for improvement of outcome for patients with Cutaneous 
Malignant Melanoma lies in the prevention of systemic metastasis.  Despite extensive 
investigation, current prognostic indicators either alone or in combination, although 
related to melanoma progression, are not sufficient to accurately predict the pattern of 
progression and outcome for any individual patient. Metastasis related death has been 
recorded in patients initially diagnosed with early stage tumour and in other patients 
many years after initial tumour removal. The trouble finding a predictable pattern in 
the puzzle of melanoma progression may possibly be linked to the fact that most of 
the material studied for prognosis is either, cutaneous primaries or metastatic deposits 
rather than the melanoma cells in the circulatory system which are responsible for 
disease progression. In this review article we discuss the potential use of circulating 
tumour cell (CTC) detection and quantification for identifying patients at risk of 
metastatic deposits. We also discuss current therapies for the treatment of metastatic 
melanoma and analyse how the use of CTCs may be used to evaluate the effectiveness 
of current therapies and to pinpoint patients who require further treatment. 
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Introduction 
Cutaneous Malignant Melanoma (CMM) is the most severe of all skin cancers, 
accounting for 80% of skin cancer related deaths.Lewis [1]. CMM is the most 
common cancer in Australia for persons aged 15-39 and the deadliest cancer affecting 
young Australian males. In 2006 in Australia there were 10,000 new cases, 1,700 
deaths and rates are continuing to rise [2]. In the United States CMM is an emerging 
problem as the incidence has increased more than that of any other cancer over the 
past two decades. More specifically, in 2005 the American Cancer Society recorded 
approximately 59,580 new cases and over 7,910 new deaths [3, 4]. 
 
CMM is often aggressive, unpredictable and difficult to treat. Mortality rates continue 
to remain high due mainly to progression of multiple drug resistant metastases for 
which the cure rate is currently less than 20% [5, 6]. Much effort has been put into 
identifying prognostic factors that correlate with clinical outcomes to enable The 
American Joint Committee on Cancer (AJCC) to devise an accurate TNM clinical 
staging system. Histopathologists determine the tumour thickness (T) component of 
this system, which most accurately characterises the CMM once excised [7]. Other 
features including ulceration, mitotic rate, clinical or surgical detection of lymph node 
(N) or distant metastasis (M) make up the information needed to stage and thus 
prognosticate and treat appropriately [8]. Other details including sex, age, LDH levels 
and anatomical location of the melanoma and metastases, residual disease following 
initial resection and genomic changes in the primary tumour have been linked with 
prognostic changes but so far have little material influence on treatment plans [9-11]. 
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Despite extensive investigation, the above factors either alone or in combination, 
although related to melanoma progression are not sufficient to accurately predict the 
pattern of progression and outcome for any individual patient. Metastasis related 
death has been recorded as long as 35 years following initial removal of the primary 
tumour (uveal melanoma) [12]. The trouble finding a predictable pattern in the puzzle 
of melanoma progression may possibly be linked to the fact that most of the material 
studied was based on either cutaneous primaries or metastatic deposits rather than the 
quantity and phenotype of melanoma cells in the circulatory system. Circulating 
tumour cell (CTC) detection and quantification may hold the key to identifying 
patients at risk of metastatic deposits. Analysing CTCs has the potential not only to 
pinpoint patients who may require further treatment but evaluate the effectiveness of 
current therapies. 
 
Current Methods of Treatment of Melanoma 
CMM, generally referred to as melanoma, arises from melanocytes, cells of neural 
crest origin which migrate into the skin [13]. CMM can grow laterally in the 
epidermis or vertically through to the dermis ultimately leading to vascular invasion 
and metastatic disease. Stage 1 or 2 melanoma can be cured by wide surgical excision 
resulting in a 50-100% 5 year survival rate, decreasing with increasing tumour 
thickness [14]. Following surgery, patients are examined and depending on the 
histological features of the primary they may have further investigations including 
sentinel node biopsy, CT or PET for staging purposes [14]. Patients with tumours 
under 2mm do not require any investigations for staging as at this level imaging is not 
specific enough to identify metastases accurately, even though up to 44% of these 
people eventually die from metastatic disease despite having the primary removed 
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[14, 15]. Patients diagnosed with lymph node or systemic metastasis have a 5 year 
survival rate that plummets to between 5-60% [8, 16]. So far however, there is no 
specific gene within the tumour cells in the primary that can accurately predict the 
aggressiveness of the tumour [17]. 
 
There is no doubt that a cancer’s mortality rate is determined by the speed of 
metastasis [18, 19].  In all tumours, millions of tumour cells (reported to be around 
4x106 per gram of tumour over a 24 hour period [20, 21]) invade the venous or 
lymphatic circulation very early in tumour development and result in disease 
progression [22-25]. Moreover a meta-analysis has shown that the number of CTCs in 
a patient’s peripheral blood increases with increasing stages of melanoma [26]. 
Despite these recent advances there is still much to discover, including the phenotype 
of the melanoma CTCs that are able to stay dormant in the circulation for many years, 
evading the immune system, and the events leading to their activation, seeding and 
proliferation in distant bodily organs. 
 
Once the tumour metastasises, and thus needs systemic treatment, there is a 
considerable lack of investigations available to give information to measure the 
current disease load and response of treatments.  The AJCC currently uses metastatic 
site and serum LDH to put a number to the 5 year survival rate for prognostication 
purposes [8]. Treatment is measured in terms of the Objective Response Rate (ORR) 
defined as the percentage of patients with identifiable tumour shrinkage plus the 
percentage of patients with complete tumour disappearance following treatment [27].  
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Analysis of volume and phenotype of CTCs could have a place in monitoring current 
treatment responses. Additionally, development of markers that can reliably detect 
CTCs could potentially identify which tumours may respond to current treatments and 
highlight possible avenues for future treatment development. Current treatments are 
purely palliative as they have a response rate under 20% and do not have a significant 
survival benefit [28, 29]. CTCs as a marker could be used to determine whether the 
gold standard treatment DTIC is effective in treating disease as to date there is no 
placebo controlled trial to confirm its efficacy [28, 29]. Interleukin 2 (IL2) 
immunotherapy, a treatment developed in the 1990’s has shown an overall response 
rate of 16% and these responders had a progression free period of over 5 years[28]. 
As IL2 is known to have severe side effects it is restricted to those with an excellent 
performance status and organ function, but ideally it would be desirable to have a way 
to identify who will respond. There is a possibility that analysis of CTCs would 
provide a way of identifying responders so that this treatment can be given to those 
most likely to benefit.  
 
Vaccine treatment has been used in the effort to find a treatment that improves 
survival. Due to the heterogeneity of melanoma cells there has been a limited 
response rate of 12% with a mean increased overall survival (OS) of 21.3 months, 
triple that of DTIC [28, 30]. With further analysis of CTCs the genetic identity of the 
responders to IL2 or vaccines could be identified and vaccines could be developed to 
target the markers found in patient subsets.  
 
B-RAF inhibitors are an exciting new mode of treatment targeting a mutation in B-
RAF, an oncogene that promotes growth and angiogenesis when activated [31]. A 
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selective inhibitor of active B-RAF, PLX4032 has been shown to have a 78% 
response rate in phase 1 trials and phase 2 and phase 3 trials began in September 2009 
and January 2010. Despite their initial success however, reports indicate that there is 
rapid acquisition of drug resistance resulting in a restriction of therapeutic response to 
an average 8 months [32-34]. There is, therefore, an urgent need for early detection of 
resistance to kinase inhibitors. The method currently used to evaluate the response of 
this treatment is an overall Response Evaluation Criteria in Solid Tumours (RECIST) 
which uses current imaging methods to find measurable lesions and monitor size 
before and after treatment. CTCs have the potential to enhance this process by using 
tumour cell load to monitor microscopic response to treatment and early acquisition of 
drug resistance, while current methods can only measure macroscopic metastasis 
presence/shrinkage. 
 
 
Knowledge to date on the process of melanoma cell metastasis – not as simple as 
originally thought. 
 
Understanding the processes that lead to metastasis are important for choosing 
significant molecular markers to characterise CTCs for future treatment strategies. 
The process of metastasis in melanoma requires loss of intracellular adhesion, dermal 
invasion, migration from the primary site, intravasation, intravascular survival, 
attachment to the vasculature of target tissues, migration into target organs, 
proliferation and angiogenesis at the target site [35]. Of particular relevance in this 
instance is the process of tumour cell dissemination to seed metastasis. 
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Melanoma cells arise in the epidermis, where initially, like melanocytes, they are 
tethered tightly to the surrounding melanoma cells, melanocytes and keratinocytes by 
a complex network of desmosomes, the adhesion molecules and gap junctions which 
allow transfer of melanin [22, 36, 37]. Once melanoma cells enter the invasive stage 
they progressively loose these adhesion surface interactions [38-40]. One of the key 
surface proteins, Epithelial Cadherin (E-Cadherin/CDH1), is bound via its 
cytoplasmic tail to α- catenin and β-catenin which links it directly to the actin 
cytoskeleton of the cell [41]. In fact the switching of E-Cadherin/CDH1 with Non-
epithelial Cadherin (N-Cadherin/ CDH2) indicates the initiation of an epithelial to 
mesenchymal transition for the cell (EMT) [37]. The EMT process, initially utilized 
by migrating cells during embryonic development, allows the cell to transform from a 
polarised epithelial cell to a contractile, motile mesenchymal cell and this process is 
triggered by secretion of growth factors from fibroblasts and macrophages (e.g. 
hepatocyte growth factor (HGF), and/or fibroblast growth factor (FGF)). This 
secretion induces intracellular transduction pathways (Transforming growth factor-β 
(TGF-β), Platelet Derived Growth Factor (PDGF), Wnt and Notch) which in turn 
activate transcription factors (Snail and E47) [37, 42]. This cascade leads to the 
aforementioned switching of E-Cadherin to N-Cadherin allowing the cell to detach 
from the epithelium and migrate into the circulation leading to tumour progression 
[22, 43]. 
 
When melanoma cells detach from the primary tumour and enter the bloodstream or 
lymphatics they can do so actively or passively [18]. Passive entry occurs when cells 
are simply dislodged from the primary tumour due to increased blood flow and low 
CDH1 levels [18]. By contrast, active migration occurs in cells when NEDD9, a 
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melanoma metastasis protein, forms a complex with DOCK-3, a guanine nucleotide 
exchange factor, to activate Rac, a GTPase which acts on actin assembly, actomysin 
contractility and microtubules [44]. The result of Rac activation is that the cell 
becomes mobile and elongated so that it can pass between other cells [44]. The 
movement of these cells is assisted by matrix metalloproteinases that destroy integrins 
(cell receptors that mediate attachment to surrounding cells) and other extracellular 
materials [45]. 
 
The next step in the active migration process is the attraction of the tumour cells to 
lymph and/or blood vessels, a process mediated by ligand-receptor interactions 
between tumour cells and the stroma or endothelial cells. The tumour cells secrete 
Colony Stimulating Factor 1 (CSF-1) and growth factors such as Epithelial Growth 
Factor (EGF) which activate the formation and proliferation of tumour associated 
macrophages in the stroma. These macrophages secrete growth factors, cytokines, 
chemokines and enzymes that regulate tumour growth, angiogenesis, invasion and/or 
metastasis [22, 46]. 
 
Whether cells actively move toward and into surrounding blood vessels or whether 
this process is passive and coincidental may be significant. Expression of the genes 
and production of the complexes mentioned above, that result in active entry, may 
enhance survival of the cell once it is in the blood and increase metastatic ability. 
Thus markers for the above factors may provide a better measurement of metastatic 
potential than sheer number of circulating cells. 
 
10 
 
In order to investigate circulating tumour cells in more detail, models have been 
developed in which a tumour and its vascular system are isolated and blood vessels 
are monitored so as to quantify and characterise the cells entering and exiting the 
tumour [18, 20, 47]. Notably, a large volume (3-4x106) of cells are shed every day, 
with few of these developing into clinically detectable metastases. Characterisation of 
these circulating cells in patients with advanced breast and prostate cancer indicates 
that they are predominantly apoptotic and necrotic and are unlikely to survive [48-51]. 
Furthermore, it is believed that the bulk of circulating cells are destroyed by sheer 
stress; moreover circulating immune cells prevent all but the most proficient from 
producing secondary colonies [38, 52]. 
 
Nevertheless, some cells do survive for long times in the vasculature, though not 
independently, with the exception of hematopoietic cancers [38, 53]. Tumour cells are 
usually found in clumps, also known as circulating tumour microemboli, which are 
hidden beneath a “cloak” of platelets and leukocytes which may enhance survival [38, 
54, 55]. Another factor promoting melanoma cell survival in the vasculature is 
evasion of natural killer (NK) cells, whose primary role is to pinpoint and destroy 
cancer cells. One mechanism melanoma cells have is intracellular retention of the 
NKG2D ligand which is usually expressed on the surface of infected or mutated calls 
and targets the cell for NK cell mediated destruction [56]. Another way it evades the 
immune system is by not expressing the oncostatic M receptor, which, when activated 
by IL-6 prevents cell division [6, 57]. 
 
It is well established that a melanoma cell may invade the circulation and survive 
without clinical evidence of a primary tumour, and so, not infrequently a patient may 
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have metastatic melanoma without a known cutaneous primary site [58, 59]. In fact, 
melanoma can still be lethal even when tumours cannot form due to the patient having 
an inbuilt inability for the tumours to form a vascular supply [4]. In this case the 
patient developed high levels of cells in the blood and CSF and eventually succumbed 
to renal failure from tumour lysis syndrome. Taken together with the fact that 9-45% 
of surgical excisions result in recurrences and up to 8% of melanoma in situ diagnoses 
result in recurrence, it is clear that circulating cells have a significant prognostic value 
and a more detailed investigation of the phenotype of actively metastasizing CTCs 
would have major implications for future clinical diagnoses and treatments [60-65]. 
 
Current knowledge of the genetic identity of melanoma cells 
 
The question remains then, how do we identify the few CTCs that are capable of 
surviving in the circulation and metastasizing?  The genetic factors needed to survive 
in the circulation must be different to those needed to proliferate in situ and also 
separate from those needed to establish a secondary tumour, so the cells surviving in 
the circulation for an extended period of time are the ones needed to identify this 
phenotype and survival advantage. Analysis of the genes expressed in circulating cells 
compared to primary and secondary tumour cells is one way of highlighting some of 
the changes in phenotype and adaptability necessary for their survival. This approach 
has been supported by observations of the different genes expressed in primary versus 
circulating cells from the same patient with melanoma [23, 24]. It has also been 
shown that there are subpopulations of cells within a primary tumour that resemble 
metastatic deposits; the cells are changed enough that they will survive to metastasis 
[66]. Alternately, there is no reason that any cancer cell cannot develop the ability to 
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metastasise, even prior to clinically detectable tumour formation [67]. Therefore, 
there is a possibility that for heterogeneic tumours like melanoma, an unstable, 
genetically variant and invasive cell could survive in the circulation but not exist in 
any volume in the primary tumour [22, 68]. Genetic changes that provide an edge in 
metastasis and proliferation at a secondary site may not be advantageous in the 
primary tumour and thus too rare to be identified in its population-averaged gene 
expression profile [22]. The preponderance of patients with in situ or occult 
melanomas (discussed in previous sections in more detail) supports these theories. 
 
In the last few years a number of researchers have shown the existence of a subset of 
tumour initiating melanoma stem cells within the primary tumour that possess two 
important features. One of these features is the ability to self renew as well as 
differentiation into cancer progenitor cells. The other of these features is the innate 
resistance to chemotherapy and radiation [69-72]. These rare cancer stem cells are 
present early on (rather than immediately prior to metastasis as originally thought) 
and effectively manage the metastatic process when the detectable bulk of the tumour 
visible by current techniques has been successfully treated [73]. They evade therapy 
due to their stem cell properties of slow turnover and chemotherapy resistance, and 
upon reaching their destination would act as a seed for metastasis formation [74]. 
Melanoma stem cells have been identified in primary tissue and cell lines by 
expression of recently identified melanoma stem cell markers, namely, Multi-Drug 
Resistance gene product 1 (MDR-1) [75], CD20 [70, 76-78], CD44/CDH5/VE-
Cadherin [78, 79], CD133 [70, 77, 78, 80], ABCB5 [75, 77, 78, 80], ABCC2 [75], 
ABCG2 [70, 80], human telomerase reverse transcriptase (hTERT) [75], nanog [75] 
and JARID1B [81]. However unlike normal stem cells, cancer stem cells may be 
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termed stem-cell like since they have mutations in key signalling pathways that may 
lead to ‘phenotype instability’ enabling cancer cells to switch their phenotype in 
response to microenvironmental cues [82]. 
 
Evidence of melanoma stem cells in the circulation of melanoma patients remains to 
be demonstrated but similar cells have been found in the bone marrow in breast 
cancer patients [83]. 
 
Melanoma markers identified 
 
A large volume of studies have been dedicated to identification of markers with 
sufficient sensitivity and specificity to accurately predict melanoma progression. Even 
though many of these markers were identified from primary lesion tissues, these 
markers have been tested for in some CTC studies [84-87]. Mentioned previously, 
melanocytic and melanoma markers commonly used for qRT-PCR of CTCs include 
MAGE-A3 [64, 87-89], Mitf [87, 90], MART-1/Melan-A [64, 87-89], Tyr [26, 87, 
89] and most recently ABCB5 [71, 77]. As a result of high throughput analyses of 
melanoma progression pathways several key pathways have been identified including 
epithelial-mesenchymal transition [91] but many of these are yet to be tested as 
informative for CTC analysis using either gene expression or whole cell detection 
techniques [17, 86, 92, 93]. Key amongst these pathways are: tyrosine kinase receptor 
(TKR) pathways (e.g. VEGFR, ERBB2 and the TGFβ receptor) [37], the 
Ras/Raf/MEK/ERK pathway [37], the PI3K/Akt/PTEN/mTOR pathway [37], cell 
cycle regulation pathways (Rb/p53/p16INKA/p14ARF/HDM2/CXCR4/CDC42) [94], 
epigenetic gene expression regulation and DNA repair (DNA methylation, histone 
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mitochondrial pathway and RNA interference) [95, 96], apoptotic pathways (e.g. 
death receptors: FAS, TRAILR, TNFR; mitochondrial pathway: Bcl2 family) [97], 
and epithelial to mesenchymal transition (CDH2, SPP1 and SPARC) [98]. Epithelial 
to mesenchymal transfer (EMT) has been thought to be the key to metastasis by 
giving malignant melanoma cells stem like capabilities to migrate within and through 
tissues. In 2010 Roesch [81] has added a further marker to this bank, JARID1B, 
which identifies slow cycling melanoma stem cells, first identified by Adams and 
Strasser [99] in 2008. This marker is expressed on melanoma cells which are slow to 
divide and so also resistant to current treatments but was not linked with the classic 
EMT signature or any other stem cell markers suggested to date.  
 
It is possible that if these pathways are analysed further in CTCs that they may play a 
role in CTC survival, proliferation and intra- and extravasation. Furthermore, with 
continuing discovery of markers specific to melanoma stem cells and metastatic 
pathways a marker may be found that reliably detects metastatic melanoma which 
would be useful especially in detecting amelanocytic melanoma where there are only 
small levels of melanocytic gene expression and tracking down CTCs in patients with 
no primary melanoma. Moreover melanoma stem cell markers may be able to be used 
to identify residual melanoma in patients with complete regression according to the 
current radiological methods of monitoring treatment effectiveness. 
 
In summary, conventional staging and treatment of melanoma is not particularly 
precise and effective. This has the potential to be dramatically improved by 
investigating molecular and cellular markers/pathways which lead to tumour 
progression. Such markers could include proteinases (proteinases of the plasmin 
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system, serine proteinases and matrix metalloproteinases) which degrade the 
extracellular matrix on the path to the circulation or create a basement membrane at 
the target site. Another possibility is the analysis of the superficial glycoproteins, 
factors responsible for cell adhesion (integrins) and intercellular communication 
(cadherins). Furthermore neoangiogenesis markers such as vascular endothelial 
growth factor (VEGF), endoglin (CD105), a transmembrane glycoprotein which is a 
component of the receptor for activating TGFβ, as well as neuropilin (NRP1), the co-
receptor for VEGF could be included [37]. As previously described, markers of EMT 
transition (Twist, PI3K/Atk and CDH1) and melanoma stem cell markers (e.g. 
ABCB5) may also be of value in this analysis. 
 
It has been reported that alteration of the pathways involved in melanocyte 
development may be the key to acquiring metastatic potential in melanoma [13, 100-
103]. In fact, melanoma metastasis mimics the migratory capacity of neural crest 
cells, which are the embryonic precursors of melanocytes. Furthermore, some of the 
genes responsible for melanocyte development have been implicated in the process of 
melanoma formation, for example, PAX3 [87, 98, 104-106], Mitf [82, 87, 98], 
dopachrome tautomerase (DCT) [98, 106] and SOX10 [98]. These genes maintain a 
population of melanoblasts during migration from the neural crest during 
embryogenesis and from the hair follicle niche in mature skin. It is possible that these 
cells may also be the key to understanding melanoma stem cell maintenance and 
migration. The developmental genes and the signalling pathways required for 
maintenance of stem cell niches may help in the understanding of melanoma 
heterogeneity and the biological properties of melanoma cell subpopulations [82].  
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The use of CTCs as a prognostic indicator – valuable or not? 
 
From past studies it has been noted that positivity for CTCs is not a prognostic 
indicator in itself i.e. not all circulating cells establish successful metastases. 
Circulating breast cancer cells have been found many years after mastectomy where 
only 1% develops recurrence though patients with circulating cells shortly after 
mastectomy are more likely to develop recurrence [107]. In uveal melanoma the 
quantity and genetic profile was more predictive than mere presence of CTCs in the 
blood, which was relatively inaccurate [108]. Moreover there is not yet any evidence 
that tumour progression is linked to increased genetic marker levels in the circulating 
CTCs. A more thorough analysis of the phenotype of CTCs associated with 
progression is still needed to confirm whether this may lead to a reliable marker. It is 
possible that increased marker level is due to change in phenotype rather than increase 
in number of CTCs. 
 
A more comprehensive set of analyses of CTCs are required to better understand the 
diagnostic and prognostic significance of CTCs. We propose that these issues be 
addressed by isolation, characterisation and quantification of circulating melanoma 
cells. Additionally, application of newly identified markers to the long term follow up 
of patients will delineate the metastatic potential of circulating melanoma cells and 
their usefulness as a prognostic indicator. 
 
Conclusion 
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This article addresses the transformation of cells from clinically latent to metastatic 
proliferating cells. We hypothesise that the ability of circulating melanoma cells to 
become activated, proliferate and migratory from a clinically latent cell depends on 
several key genes. An alternate hypothesis is that malignant cells disseminate from 
the primary tumour early in tumour development and remain in a clinically latent state 
until either the cells themselves or the host environment is receptive to metastasis. 
Quintana [109] showed that at least 25% of randomly harvested human melanoma 
cells from 12 different patients will re-establish a melanoma when xenotransplanted 
as single cells into severely immuno-compromised mice. Since this is unlikely in 
humans with an immune response and these cells did not form metastases, it is 
important to identify the pathways responsible for transforming melanoma stem cells, 
which are normally clinically latent, into cells capable of metastasis. Microarray 
analysis of tumour cells from different stages of melanoma has demonstrated that the 
genetic signature of the cell changes as the tumour progresses [24]. This adds to the 
evidence that analysing the phenotype of circulating cells may be beneficial in 
prognosis. 
 
Current methods use only histological analysis and imaging to determine patient 
prognosis. While novel therapies are continuing to be trialled for the treatment of 
melanoma, mortality rates remain high [110]. Measurement of circulating melanoma 
cells has not yet been refined sufficiently so as to make it an effective diagnostic or 
prognostic tool but there is still potential for further discoveries to make this leap. 
Future studies involving isolation and gene expression analysis of circulating cells 
may provide crucial information about the changes in genes required for metastatic 
success and the numbers of cells expressing these genes needed to establish successful 
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metastasis. As well as the benefit identification of these genes may make to 
prognostic information, they may also be harnessed as targets for future treatment 
regimes. 
 
Markers that highlight active, metastatic cells in the circulation would potentially 
enable understanding of melanoma metastasis like that already identified for breast 
cancer. Detection of CTCs is already a significant prognostic indicator in breast 
cancer patients as it relates directly to disease status and treatment efficacy [111, 112]. 
Indeed it more reliably correlates with overall survival than current imaging methods 
as they are relatively insensitive, especially in early metastasis [113, 114]. Finally, it 
is important to note that most cells that enter the circulation are apoptotic or necrotic 
yet current, conventional qRT-PCR is unable to exclude these cells. Preferentially, a 
paradigm embracing the isolation, quantification and characterisation of melanoma 
stem cells could potentially act as a more reliable and sensitive measure of 
progression and clearance of malignant melanoma which has already undergone  
existing or newly developed therapies. 
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